Neurohormonal Blockade in Heart Failure

Overview

Journal Card Fail Rev

Date 2017 Aug 9

PMID 28785471

Citations 26

Authors

Thomas G von Lueder

Dipak Kotecha

Dan Atar

Ingrid Hopper

Affiliations

Soon will be listed here.

Abstract

A key feature of chronic heart failure (HF) is the sustained activation of endogenous neurohormonal systems in response to impaired cardiac pumping and/or filling properties. The clinical use of neurohormonal blockers has revolutionised the care of HF patients over the past three decades. Drug therapy that is active against imbalance in both the autonomic and renin-angiotensin-aldosterone systems consistently reduces morbidity and mortality in chronic HF with reduced left ventricular ejection fraction and in sinus rhythm. This article provides an assessment of the major neurohormonal systems and their therapeutic blockade in patients with chronic HF.

Citing Articles

Counteracting the Mechanisms of Heart Failure is the Most Effective Way to Decongest Patients while Improving Outcomes.

Celutkiene J, Mebazaa A, Biegus J, Ponikowski P, Davison B, Cotter G Card Fail Rev. 2025; 11:e02.

PMID: 40018521 PMC: 11865671. DOI: 10.15420/cfr.2024.19.

Long-term surrogate cardiovascular outcomes of SGLT2 inhibitor empagliflozin in chronic heart failure: a systematic review and meta-analysis.

Yan Q, Chen X, Yu C, Yin Y BMC Cardiovasc Disord. 2024; 24(1):663.

PMID: 39578752 PMC: 11583546. DOI: 10.1186/s12872-024-04316-w.

Excess long-term risk of adverse outcomes in heart failure patients with high and low levels of NT-proBNP: A 7-year follow-up study (NorthStar Trial).

Tuxen A, Malmborg M, Nouravesh N, Videbaek L, Malik M, Zahir D Int J Cardiol Heart Vasc. 2024; 53:101441.

PMID: 39228977 PMC: 11368590. DOI: 10.1016/j.ijcha.2024.101441.

Single-cell and spatial transcriptomics of the infarcted heart define the dynamic onset of the border zone in response to mechanical destabilization.

Calcagno D, Taghdiri N, Ninh V, Mesfin J, Toomu A, Sehgal R Nat Cardiovasc Res. 2024; 1(11):1039-1055.

PMID: 39086770 PMC: 11290420. DOI: 10.1038/s44161-022-00160-3.

Neurohumoral Activation in Heart Failure.

Manolis A, Manolis T, Manolis A Int J Mol Sci. 2023; 24(20).

PMID: 37895150 PMC: 10607846. DOI: 10.3390/ijms242015472.

References

Teerlink J . Endothelins: pathophysiology and treatment implications in chronic heart failure. Curr Heart Fail Rep. 2005; 2(4):191-7. DOI: 10.1007/BF02696649. View

Young M, Funder J . Mineralocorticoid receptors and pathophysiological roles for aldosterone in the cardiovascular system. J Hypertens. 2002; 20(8):1465-8. DOI: 10.1097/00004872-200208000-00002. View

Goldsmith S . Interactions between the sympathetic nervous system and the RAAS in heart failure. Curr Heart Fail Rep. 2005; 1(2):45-50. DOI: 10.1007/s11897-004-0024-5. View

Swedberg K, Hjalmarson A, Waagstein F, WALLENTIN I . Prolongation of survival in congestive cardiomyopathy by beta-receptor blockade. Lancet. 1979; 1(8131):1374-6. DOI: 10.1016/s0140-6736(79)92010-5. View

Pham I, Gonzalez W, el Amrani A, Fournie-Zaluski M, Philippe M, Laboulandine I . Effects of converting enzyme inhibitor and neutral endopeptidase inhibitor on blood pressure and renal function in experimental hypertension. J Pharmacol Exp Ther. 1993; 265(3):1339-47. View

von Lueder T, Wang B, Kompa A, Huang L, Webb R, Jordaan P . Angiotensin receptor neprilysin inhibitor LCZ696 attenuates cardiac remodeling and dysfunction after myocardial infarction by reducing cardiac fibrosis and hypertrophy. Circ Heart Fail. 2014; 8(1):71-8. DOI: 10.1161/CIRCHEARTFAILURE.114.001785. View

Bodey F, Hopper I, Krum H . Neprilysin inhibitors preserve renal function in heart failure. Int J Cardiol. 2014; 179:329-30. DOI: 10.1016/j.ijcard.2014.11.059. View

Kelland N, Webb D . Clinical trials of endothelin antagonists in heart failure: publication is good for the public health. Heart. 2006; 93(1):2-4. PMC: 1861328. DOI: 10.1136/hrt.2006.089250. View

Ikeda T, Murai H, Kaneko S, Usui S, Kobayashi D, Nakano M . Augmented single-unit muscle sympathetic nerve activity in heart failure with chronic atrial fibrillation. J Physiol. 2011; 590(3):509-18. PMC: 3379697. DOI: 10.1113/jphysiol.2011.223842. View

10.

Rouleau J, Pfeffer M, Stewart D, Isaac D, Sestier F, Kerut E . Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial. Lancet. 2000; 356(9230):615-20. DOI: 10.1016/s0140-6736(00)02602-7. View

11.

Pfeffer M, McMurray J, Velazquez E, Rouleau J, Kober L, Maggioni A . Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003; 349(20):1893-906. DOI: 10.1056/NEJMoa032292. View

12.

Zannad F, McMurray J, Krum H, Van Veldhuisen D, Swedberg K, Shi H . Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2010; 364(1):11-21. DOI: 10.1056/NEJMoa1009492. View

13.

Voors A, Gori M, Liu L, Claggett B, Zile M, Pieske B . Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction. Eur J Heart Fail. 2015; 17(5):510-7. DOI: 10.1002/ejhf.232. View

14.

Mann D, McMurray J, Packer M, Swedberg K, Borer J, Colucci W . Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation. 2004; 109(13):1594-602. DOI: 10.1161/01.CIR.0000124490.27666.B2. View

15.

Dalzell J, Seed A, Berry C, Whelan C, Petrie M, Padmanabhan N . Effects of neutral endopeptidase (neprilysin) inhibition on the response to other vasoactive peptides in small human resistance arteries: studies with thiorphan and omapatrilat. Cardiovasc Ther. 2013; 32(1):13-8. DOI: 10.1111/1755-5922.12053. View

16.

Kiowski W, Sutsch G, Hunziker P, Muller P, Kim J, Oechslin E . Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure. Lancet. 1995; 346(8977):732-6. DOI: 10.1016/s0140-6736(95)91504-4. View

17.

Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L . Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulation. 1990; 82(5):1730-6. DOI: 10.1161/01.cir.82.5.1730. View

18.

Lerman A, Kubo S, Tschumperlin L, Burnett Jr J . Plasma endothelin concentrations in humans with end-stage heart failure and after heart transplantation. J Am Coll Cardiol. 1992; 20(4):849-53. DOI: 10.1016/0735-1097(92)90183-n. View

19.

Barfacker L, Kuhl A, Hillisch A, Grosser R, Figueroa-Perez S, Heckroth H . Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases. ChemMedChem. 2012; 7(8):1385-403. DOI: 10.1002/cmdc.201200081. View

20.

Yanagisawa M, Kurihara H, Kimura S, Goto K, Masaki T . A novel peptide vasoconstrictor, endothelin, is produced by vascular endothelium and modulates smooth muscle Ca2+ channels. J Hypertens Suppl. 1988; 6(4):S188-91. DOI: 10.1097/00004872-198812040-00056. View